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The transforming growth factor- (TGF-) 
and Wnt pathways are involved in cell fate and 
tumorigenicity. A recent report indicated that a 
TGF- target gene, transmembrane prostate 
androgen induced-RNA (TMEPAI), is possibly also 
a downstream target of Wnt signaling. Although 
TMEPAI was believed to be involved in 
tumorigenicity owing to its blockage of TGF- 
signaling, how TGF- and Wnt signals affect the 
activation of the TMEPAI gene is not well 
understood. Herein, we show that the TMEPAI 
promoter is regulated synergistically by 
TGF-/Smad and Wnt/-catenin/T cell factor 
(TCF)7L2. The critical cis-element for dual signals, 
termed TGF--responsive TCF7L2 element (TTE), 
is located in intron 1 of the TMEPAI gene. TCF7L2, 
but not Smad proteins, bound to TTE, whereas the 
disruption of TTE by mutagenesis remarkably 
counteracted both TGF-- and TCF7L2-responses. 
The introduction of mutations in critical Smad 
binding elements (SBEs) blocked the activation of 
the TMEPAI promoter by TCF7L2. Furthermore, 
our DNA-protein interaction experiments revealed 
the indirect binding of TCF7L2 to SBEs via Smad3 
upon TGF- stimulation as well as its 
TGF--dependent association with TTE. We 
demonstrate that the Wnt/-catenin/TCF7L2 
pathway is preferentially able to alter the 
transcriptional regulation of the TGF--target gene, 
TMEPAI.  
 
The transforming growth factor (TGF)- 
ligands mediate their signals in cells via specific 
serine/threonine kinase receptors and intracellular 
signal transducing molecules, termed Smads (1). Each 
step of the TGF- signal transduction pathway appears 
to be subject to both positive and negative regulation 
(2,3). The TGF- family is implicated in 
embryogenesis and maintenance of tissue homeostasis 
during adult life. Thus, aberrant signaling by TGF- 
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family members is involved in various diseases 
including cancer, fibrosis, and vascular disorders (4,5). 
Although TGF- acts as a tumor suppressor by 
inhibiting cell growth, it also promotes tumor 
progression and metastasis by inducing 
epithelial-mesenchymal transition (EMT), invasion, 
immunesuppression, and blood vessel intravasation by 
carcinoma cells (2,6). 
The canonical Wnt cascade is initiated by the 
binding of Wnt ligands to their cognate receptor 
complex components such as the Frizzled family and 
low-density-lipoprotein receptor related protein 
(LRP)5/6. In the absence of canonical Wnt signaling, 
-catenin is phosphorylated, ubiquitinated, and 
degraded. Upon the activation of the canonical Wnt 
pathway, the phosphorylation and degradation of 
-catenin are inhibited. Thus, stabilized -catenin can 
accumulate to the nucleus, where it makes an active 
transcription complex with the T cell factor/lymphoid 
enhancer binding factor (TCF/LEF) family of DNA 
binding transcription factors (7). 
Transmembrane prostate androgen 
induced-RNA (TMEPAI) can interact with either 
Smad2 or Smad3 via its Smad interaction motif (SIM) 
to sequester TGF-/Smad signaling because of its 
competition with Smad anchor for receptor activation 
(SARA) for binding to Smads. Since TMEPAI is a 
direct target gene for TGF- signaling, TMEPAI seems 
to act as a molecule involved in the negative feedback 
loop of TGF- signaling (8). Except for its contribution 
in TGF- signaling, TMEPAI is known to be 
implicated in the degradation of androgen receptor 
(AR) by the recruiting of the E3 ubiquitin ligase to AR 
(9) as well as by cell growth inhibition and 
p53-induced apoptosis in a context-dependent fashion 
(10,11). In addition to TGF- stimulation, TMEPAI 
has been reported to be induced by treatment with 
androgen, introduction of mutant p53, or activation of 
the Erk pathway (11-13). Recently, TMEPAI was 
reported to be highly expressed in the intestinal polyps 
of Apc
Min/+
 mice (8,14). Thus, these reports supported 
the theory that the TMEPAI gene might be one of the 
canonical Wnt target genes. Furthermore, TMEPAI 
expression was increased in breast cancer, colon cancer, 
and renal cell carcinoma in humans (13,15,16). 
It has been reported that the canonical 
Wnt/-catenin pathway collaborates with either TGF- 
or BMP signaling in an agonistic or antagonistic 
fashion. In an agonistic manner, the complex of 
-catenin and the TCF/LEF family interacts with Smad 
proteins to coordinate the transcription of target genes 
(17-20), whereas the transcript of the Id1 gene induced 
by BMP is antagonistically regulated by Wnt3a, which 
might inhibit the transcriptional complex formation on 
the BMP-responsive element of the Id1 gene (21). 
Given the recognized role of TMEPAI in the 
regulation of the TGF- pathway, we explored the 
possible role of the canonical Wnt pathway in the 
modulation of TMEPAI transcription. Our results 
indicate that the TMEPAI gene is synergistically 
transactivated by TGF-/Smad and 
Wnt/-catenin/TCF7L2 at the transcriptional level. 
Furthermore, these results support the notion that 
TCF7L2 is recruited to TGF--responsive TCF7L2 
binding element (TTE) via its indirect binding to 
Smad-binding elements (SBEs) upon TGF- 
stimulation. 
 
EXPERIMENTAL PROCEDURES 
Plasmid construction- Constitutively 
active activin receptor-like kinase 5 (ALK5ca)/V5, 
Flag-Smad2, Flag-Smad3, Flag-Smad4, (CAGA)12-luc, 
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Flag-Smad2exon3, HA-TCF7L2, 
HA-TCF7L2(1-30) and -catenin were described 
previously (22-26). Myc-TCF7L2 was kindly gifted by 
Dr. Watanabe (27). For -1972TMEPAI-luc and 
-607TMEPAI-luc, the fragments from -1972 to +67 
and from -607 to +67 (the sequence information of 
NC_000068 in NCBI Reference Sequence is referred) 
were respectively amplified using TMEPAI gene in 
BAC mouse genomic library as a template and cloned 
into pGL3-basic (Promega). pGL3ti-850 was 
constructed by the ligation of the fragment from +447 
to +1294 of mouse TMEPAI gene with pGL3ti (28). 
For -607TMEPAI-luc-850 and -607TMEPAI-luc-850r, 
the fragment from +447 to +1294 of mouse TMEPAI 
gene was put behind the 3’ end of the luciferase gene in 
-607TMEPAI-luc at both orientations. Other plasmids 
described were constructed by PCR-based 
amplification. After generation of all mutants, the 
sequences in each plasmid were confirmed. 
Cell culture- MDA-MB-468, SC3, 293T 
and COS7 cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM, Invitrogen) containing 10% 
fetal calf serum (FCS, Invitrogen) and non-essential 
amino acids (NEAA, Sigma). HepG2 cells were 
maintained in minimum essential medium (Sigma) 
containing 10% FCS, NEAA and sodium pyruvate. For 
selection of stable transformants with lentiviral vectors 
in MCF10A1, the cells were cultured in the presence of 
1 g/ml puromycin (Sigma). Smad3-deficient mouse 
embryonic fibroblasts (Smad3KO-MEFs) were 
established using Smad3KO mice which were kindly 
provided by Dr. A. B. Roberts (29). In parallel, 
establishment of MEFs from wild-type mice was also 
carried out. Both MEFs were cultivated in DMEM 
containing 10% FCS and NEAA. MCF10A1 cells were 
maintained by the method described previously except 
for use of 5 M forskolin instead of cholera toxin (30). 
Transcriptional reporter assays- One 
day before transfection, HepG2 cells were seeded at 1.0 
x 10
5
 cells/well in 12-well plates. The cells were 
transfected using FuGENE 6 (Roche). Where indicated, 
5 ng/ml TGF-3 was added into the wells 24 h after 
transfection. Subsequently, the cells were cultured in 
the absence of FCS for 18 h. In all experiments, 
-galactosidase (pCH110, GE Healthcare) activity was 
measured to normalize for transfection efficiency. Each 
transfection was carried out in triplicate and repeated at 
least twice. The transfection into MDA-MB468 cells 
and MEFs was performed according to the method of 
the transfection to HepG2 cells except for seeding the 
cells at 2.5 x 10
5
/well in 6-well plate. 
 Immunoprecipitation and western blotting-
 To detect interactions among proteins, 
plasmids were transfected into COS7 cells (5 x 10
5
 
cells/6 cm dish) using FuGENE 6. Forty hours after 
transfection, cells were lysed in 500 l of TNE buffer 
(10 mM Tris [pH 7.4], 150 mM NaCl, 1 mM 
ethylenediamine-N’, N’, N’, N’-tetraacetic acid 
[EDTA], 1% NP-40, 1 mM 
phenymethylsulfonyl-l-fluoride [PMSF], 5 g/ml 
leupeptin, 100 U/ml aprotinin, 2 mM sodium vanadate, 
40 mM NaF and 20 mM -glycerophosphate). Cell 
lysates were pre-cleared with protein G-sepharose 
beads (GE Healthcare) for 30 min at 4°C, and then 
incubated with anti-Flag M5 antibody (Sigma) for 2 h 
at 4°C. Protein complexes were immunoprecipitated by 
incubation with protein G-Sepharose beads for 30 min 
at 4°C followed by three washes with TNE buffer. 
Immunoprecipitated proteins and aliquots of total cell 
lysates were boiled for 5 min in sample buffer, 
separated by SDS-polyacrylamide gel electrophoresis 
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(SDS-PAGE) and transferred to Hybond-C Extra 
membrane (GE Healthcare). Membranes were probed 
with primary antibodies. Primary antibodies were 
detected with horseradish peroxidase-conjugated 
secondary antibodies and chemiluminescent substrate 
(Thermo Scientific). Protein expression in total cell 
lysates was evaluated by western blotting. 
 DNA affinity precipitation (DNAP)- COS7 
cells were seeded at 1.5 x 10
6
 cells/10 cm-dish one day 
before transfection. The cells were transfected using 
FuGENE 6. Forty hours after transfection, the cells 
were lysed in 1 ml of TNE buffer. The cell lysates were 
precleared with 12 g/ml poly(dI•dC) and streptavidin 
agarose (Sigma) for 30 min, and incubated with 24 M 
biotinated (SBE)3(TTE) or biotinated (mSBE)3(TTE) 
for 2 h at 4°C. Subsequently, streptavidin agarose was 
added to the reaction mixture and incubated for 30 min 
at 4°C. After precipitates were washed with TNE 
buffer three times, precipitates and aliquots of total 
lysates were separated by SDS-PAGE. Then, proteins 
were transferred to the membrane. The membrane was 
incubated with the indicated primary antibodies. 
Primary antibodies were detected as described above. 
The sequences of biotinated (SBE)3(TTE) and 
biotinated (mSBE)3(TTE) are following; biotinated 
(SBE)3(TTE), 
5’-biotinatedTTTTAGCCAGACAAAAAGCCAGAC
ATTTAGCCAGACATTTTATGAGTCAAAGT-3’/3’-
AAAATCGGACGTTTTTCGGTCTGTAAATCGGTC
TGTAAAATACTCAGTTTCA -5’, biotinated 
(mSBE)3(TTE), 
5’-biotinatedTTTTAGCtacatAAAAAGCtacatATTTA
GCtacatATTTTATGAGTCAAAGT-3’/3’-AAAATCG
atgtaTTTTTCGatgtaTAAATCGatgtaTAAAATACTC
AGTTTCA- 5’. 
 Chromatin immunoprecipitation (ChIP) 
assay- HepG2 cells were stimulated with 5 ng/ml 
TGF-3 for 1 h, and fixed by adding formaldehyde to 
the medium to a final concentration of 1%. Fifteen 
minutes after protein-DNA cross-linking at 37°C, 
glycine was added to final concentration of 125 mM. 
Then, the cells were rinsed with PBS once and lysed 
into Nuclei lysis buffer (50 mM Tris-HCl [pH 8.0], 10 
mM EDTA, 1% SDS, 10 g/ml leupeptin, 12.5 g/ml 
aprotinin) for 10 min at 4°C. Chromatin was sonicated 
till the average length of input DNA became less than 
500 bp in size. Then, the control IgG, anti-TCF7L2 
antibody (Upstate Biotechnology) or anti-RNA 
polymerase II antibody (clone CTD4H8, 
Upstate/Millipore, #05-623) was used for the 
immunoprecipitation. After purification of 
immunoprecipitated DNAs, primers specific for 
detection of the TMEPAI promoter including TTE or 
the TCF7 promoter including TBE were used for 
amplification of DNA fragments. Primers used here 
were 5’-CTCCACTCAACCAAATGTCC-3’ and 
5’-TTGGTTCAGTCTGGCTGAGA-3’for the 
TMEPAI promoter and 5’- 
AAGGAAGTCCCTGATTGGCA -3’ and 5’- 
TGTGAACTGTATCGTGCCCA -3’ for the TCF7 
promoter. 
 Apc
Min/+
 mice- Apc
Min/+
 mice which 
spontaneously show adenomas in the small intestine 
were sacrificed at 16-weeks of age. Then, polyps were 
isolated to prepare total RNAs. As a control, intestinal 
mucosa from wild-type mice was collected from total 
RNA preparation. 
 RNA preparation and RT-PCR- Total 
RNA was extracted using ISOGEN (Wako). Reverse 
transcription was carried out by using a High-Capacity 
RNA to cDNA Kit (Applied Biosystems). PCR was 
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performed using ExTaq polymerase (Takara) as 
described by the manufacturer. Primer sets to amplify 
TMEPAI, -actin and TCF7L2 cDNAs were followed: 
for human TMEPAI; 
5’-GATCATCATCATCGTGGTGG-3’ and 
5’-GATCATCATCATCGTGGTGG-3’, for human 
-actin; 5’-CAAGAGATGGCCACGGCTGCT-3’ and 
5’-TCCTTCTGCATCCTGTCGGCA-3’, for human 
TCF7L2; 5’-CAAATCCCGGGAAAGTTTGG-3’and 
5’-GCGTGAAGTGTTCATTGCTG-3’, for mouse 
TMEPAI; 5’-GTGATGATGGTGATGGTGGT-3’ and 
5’-ATCAGACAGTGAGATGGTGG-3’, for mouse 
-actin; 5’-GCTCATAGCTCTTCTCCAGGG-3’ and 
5’-TGAACCCTAAGGCCAACCGTG-3’.  
Lentiviral shRNAs for TCF7L2- The 
lentiviral vectors for TCF7L2 shRNA 
(TRCN0000061894, TRCN0000061895, 
TRCN0000061896 and TRCN0000061897) and 
non-targeting shRNA (SHC002) were from Sigma. 
Lentiviral vectors expressing shTCF7L2 were 
transfected into 293A cells together with psPAX2 and 
pMD2.G. Four different lentiviruses were 
simultaneously incubated in DMEM containing 
polybrene (8 g/ml) for 2 h and then added to dishes. 
Twelve hours after infection, cells were washed and 
cultured in medium. Infected MCF10A1 cells, which 
became puromycin-resistant, were used for 
experiments. 
 
RESULTS 
Identification of the TGF- responsive region 
within the first intron of the TMEPAI gene We 
have previously reported that TMEPAI is one of the 
early-response genes to TGF- signaling (8,25). Since 
we principally used HepG2 cells in the following 
experiments, we investigated whether TMEPAI mRNA 
in HepG2 cells could be induced by TGF-. As seen in 
Figure 1A, TMEPAI mRNA was transiently induced 
by TGF-. Likewise, SC3 cells, which are capable of 
responding to androgen, also showed induction of 
TMEPAI mRNA upon TGF- stimulation (Fig. 1B). 
Because the sequences of the TMEPAI promoter from 
the transcriptional initiation site (+1) to -850 are highly 
homologous in human and mouse, we cloned the 
fragment from +67 to -1972 using the mouse BAC 
clone including the TMEPAI gene and inserted it into 
the pGL3-basic vector (-1972TMEPAI-luc) (Fig. 1C). 
In parallel, we made one deletion mutant, termed 
-607TMEPAI-luc. When we investigated whether these 
regions in the mouse TMEPAI promoter included 
TGF--responsive element(s), the activity of neither 
-1972TMEPAI-luc nor -607TMEPAI-luc was induced 
by TGF- (Fig. 1D), resulting in the region from +67 to 
-1972 of the TMEPAI gene failing to respond to 
TGF-. 
When the first intron was compared between 
human and mouse, the beginning 850 nucleotide 
sequences were highly conserved (Suppl. Fig. 1). Thus, 
we made a luciferase reporter construct including the 
region spanning from +447 to +1294 in the TMEPAI 
gene (pGL3ti-850) (Fig. 1E). The activity of 
pGL3ti-850 was drastically potentiated by TGF-, but 
not by its related ligand BMP (Fig. 1F). In eukaryotes, 
the enhancer sequences that control mRNA 
transcription are known to function in both orientations. 
In addition, the enhancers often mediate their own 
properties even over a distance (31,32). In view of 
these observations, we addressed the question of 
whether this TGF--responsive region of the TMEPAI 
gene functions over a distance in a manner independent 
of orientation. Figure 1G shows that both orientations 
of the TGF--responsive region in the TMEPAI gene 
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could retain the functional capacity as an enhancer 
even though this region was connected to the 3’ end of 
the luciferase gene. 
The TGF- signal can be transduced to the 
nucleus via the intracellular signaling molecules Smad2, 
Smad3, and Smad4. Of these molecules, both Smad3 
and Smad4 are known to bind to specific DNA 
elements on the promoter of their target genes (22,28). 
To investigate whether the TGF--induced reporter 
activity of pGL3ti-850 depends on Smad3 and Smad4, 
pGL3ti-850 was transfected into either Smad3KO 
MEFs (Fig. 1H) or MDA-MB468 cells lacking Smad4 
genetically (Fig. 1I). In the absence of either Smad3 or 
Smad4, the reporter activity of pGL3ti-850 was not 
potentiated by TGF-, whereas the TGF- response 
was rescued by introduction of Smad3 into Smad3KO 
MEFs or that of Smad4 into MDA-MB468 cells. In 
contrast to Smad3, the transfection of Smad2 did not 
restore the pGL3ti-850 activity upon TGF- 
stimulation in Smad3KO MEFs (Fig. 2G). To further 
investigate whether Smad2 was required for 
TGF--dependent activation of pGL3ti-850, Smad2 
was knocked down in MCF10A1 cells. However, we 
could not observe any differences between cells 
transfected with control siRNAs and those transfected 
with Smad2-specific siRNAs (Suppl. Fig. 2). These 
results indicate that both Smad3 and Smad4 appear to 
be required for TGF--induced pGL3ti-850 activity.  
 Crosstalk between the TGF- and Wnt 
pathways to activate the transcription of the TMEPAI 
gene We and others found that the expression of 
TMEPAI in the intestinal polyps of Apc
Min/+
 mice is 
higher than that in the intestinal mucosa of wild-type 
mice (Fig. 2A) (8,14). Interestingly, the expression of 
TMEPAI in the region where -catenin was expressed 
at a relatively low level (red broken lines) was weaker 
than that in the region in which -catenin was highly 
expressed (blue broken lines) (Suppl. Fig. 3). Since the 
Wnt/-catenin signal in the intestinal polyps of ApcMin/+ 
mice is constitutively active, we speculated that 
TMEPAI expression might be regulated by the 
Wnt/-catenin pathway as well. To prove this 
speculation, we reduced the expression of TCF7L2, 
which is one of the critical DNA-binding 
transcriptional activators downstream of Wnt/-catenin 
signaling, in MCF10A1 cells. Subsequently, these cells 
were stimulated with TGF- for 2 h. As expected, the 
introduction of shRNAs corresponding to TCF7L2 
interfered with the basal and TGF--induced 
expressions of TMEPAI mRNA (Fig. 2B). Additionally, 
the expression of TMEPAI mRNA by TGF- in cells 
transfected with both Smad4- and TCF7L2-specific 
stealth siRNAs was weaker than that using either 
Smad4- or TCF7L2-specific stealth siRNA (Suppl. Fig. 
4), which further supported that both TGF- and Wnt 
pathways control TMEPAI mRNA expression. 
Reciprocally, TMEPAI mRNA induced by TGF- was 
further enhanced when cells were simultaneously 
stimulated with Wnt-3a although the cooperative effect 
was marginal (Suppl. Fig. 5). Thus, it is possible that 
the transcription of TMEPAI gene was regulated by 
both the Wnt and TGF- signaling pathways. Indeed, 
TCF7L2 potentiated the activity of pGL3ti-850 in a 
dose-dependent manner. However, LEF1, a member of 
the same protein family as TCF7L2, could only 
marginally activate the promoter of the TMEPAI gene 
although its expressions were relatively higher than 
those of TCF7L2 when same amount of DNA was 
transfected in cells (Fig. 2C). Since LEF1 lacks the 
C-terminal Clamp domain which TCF7L2 has (33), this 
domain might contribute to the function of TCF7L2 on 
the TMEPAI promoter activity. Therefore, we focused 
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on the effect of TCF7L2 on the TGF--induced 
TMEPAI promoter activity in the following 
experiments. 
These results prompted us to test whether 
Wnt and TGF- signaling synergistically activates the 
pGL3ti-850 reporter. Like ALK5ca, which can 
constitutively activate the TGF-/Smad pathway in the 
absence of TGF-LiCl, an activator of canonical Wnt 
signaling, increased the activity of pGL3ti-850. 
Importantly, the transfection of ALK5ca together with 
treatment of cells with LiCl revealed synergistic 
activation of pGL3ti-850 rather than its additional 
activation (Fig. 2D). Reversely, a dominant negative 
mutant of TCF7L2 (TCF7L2(1-30)), which cannot 
interact with -catenin (34), perturbed TGF--induced 
pGL3ti-850 activity (Fig. 2E). The effect of 
TCF7L2(1-30) was specific to pGL3ti-850 because 
TCF7L2(1-30) did not influence TGF--induced 
(CAGA)-luc activity (22) (Suppl. Fig. 6). -catenin 
and TCF7L2 are critical factors for regulating Wnt 
target genes, whereas Smad3 is one of the intracellular 
signal transducers of TGF- signaling. HepG2 cells 
were therefore transfected with different combinations 
of -catenin, TCF7L2, and Smad3, together with 
pGL3ti-850. After stimulation of the cells with TGF-, 
the transcriptional responses were analyzed. The 
transfection of Smad3 potentiated TGF- induced 
reporter activity. The combination of Smad3 and 
-catenin further enhanced the reporter activity induced 
by TGF-, whereas cotransfection of Smad3 with 
TCF7L2 only marginally increased TGF--induced 
pGL3ti-850 activity. When all 3 components were 
coexpressed in the cells, the basal reporter activity as 
well as the TGF--induced activity was dramatically 
augmented (Fig. 2F). It is known that Smad2 gene has 
two isoforms (i.e. long isoform termed Smad2 and its 
splicing variant termed Smad2exon3). Smad2 is also 
an intracellular signal transducer of TGF- signaling 
although unlike Smad3, it lacks the ability to bind 
directly to DNA (22,28). However, Smad2exon3 can 
acquire the ability of direct DNA binding because its 
inhibitory domain for DNA binding is deleted (23). 
When Smad2exon3 as well as Smad3 was introduced 
into Smad3KO MEFs, TGF--dependent 
transcriptional activity was restored. On the other hand, 
Smad2 did not rescue the reporter activity by TGF-. 
Besides, TCF7L2-mediated potentiation of pGL3ti-850 
activity induced by TGF- was observed when either 
Smad2exon3 or Smad3 was transfected into 
Smad3KO MEFs (Fig. 2G). Thus, the ability of DNA 
binding in Smad proteins might be necessary for Smad 
proteins to activate pGL3ti-850 reporter. 
The highest enhancer activity of the C region
 To identify a TGF- responsive element(s) 
within the region spanning from +447 to +1294 in the 
first intron of the TMEPAI gene, we divided the above 
850nt-enhancer region into 3 parts and conjugated each 
of them to the luciferase gene (pGL3ti-A, pGL3ti-B 
and pGL3ti-C) (Fig. 3A). Subsequently, each reporter 
was evaluated upon TGF- stimulation (Fig. 3B), 
expression of TCF7L2 (Fig. 3C), or expression of 
-catenin (Fig. 3D). Of the 3 parts, the C region 
possessed the highest enhancer activity when cells 
were either stimulated with TGF- or transfected with 
-catenin or TCF7L2, although the other 2 regions 
showed enhancer activities to a relatively lower extent 
as well. Thus, we focused on the C region in the 
following experiments. Since pGL3ti-850 can be 
synergistically activated by both the TGF- and Wnt 
pathways, we asked whether pGL3ti-C was also 
influenced by both pathways. When cells carrying 
pGL3ti-C together with or without ALK5ca were 
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stimulated with LiCl, the reporter activity seemed to be 
enhanced in a synergistic manner rather than in an 
additive manner (Fig. 3E). Collectively, these results 
demonstrated that the C region in the first intron of the 
TMEPAI gene possesses an enhancer of the TGF- and 
Wnt signaling pathways. 
Identification of TGF--responsive TCF7L2 
binding element (TTE) in the 1
st
 intron of the TMEPAI 
gene Since TCF7L2 could potentiate 
TGF--induced transcriptional activation of the 
TMEPAI gene, we examined which TCF/LEF binding 
element(s) (TBEs) in the C region is critical for the 
activation of the TMEPAI gene upon TGF- 
stimulation. When we looked for possible TBEs in the 
C region, we could find 4 candidates (ovals shown in 
Fig. 4A). We focused on two of those candidates 
(closed and hatched ovals shown in Fig. 4A) because 
both are highly conserved with the consensus TBE 
(5’-(T/A)(T/A)CAA(T/A)GG-3’) (35). To explore the 
possibility that these 2 TBEs contribute to 
TGF--mediated activation of the C region, we 
introduced mutations for each of the TBEs into 
pGL3ti-C. Then, cells transfected with mutant reporters 
were stimulated with TGF- to evaluate their TGF- 
responsibility (Fig. 4B). Surprisingly, the activity of 
pGL3ti-mTBE1 upon stimulation of TGF-, ectopic 
expression of TCF7L2, or a combination of both was 
obviously reduced. In contrast, the mutations in TBE2 
did not influence the reporter activity. These results 
indicate that TBE1 in the C region might play a key 
role in the TGF--induced activation of the TMEPAI 
gene as an enhancer. Therefore, TBE1 was termed the 
TGF--responsive TCF/LEF binding element (TTE) in 
the following experiments. 
Since the mutation of TTE provoked the loss 
of TGF--responsiveness in pGL3ti-C, we asked 
whether TTE alone functions as a TGF--responsive 
element. To test this hypothesis, we inserted 3 copies 
of the TTE in front of a minimal promoter 
(pGL3ti-(TTE)3) and tested this construct in HepG2 
cells. However, 3 copies of the TTE were insufficient 
for TGF--induced luciferase activity (Fig. 4C) 
although pGL3ti-(mTTE)3 lost the TGF--induced 
luciferase activity even in the presence of TCF7L2 
(Suppl. Fig. 7). Like pGL3ti-(TTE)3, 3 copies of the 
Smad binding element (SBE) in the pGL3ti vector 
(pGL3ti-(SBE)3) could not reveal strong inducibility 
upon TGF- stimulation, whereas TCF7L2 potentiated 
TGF--dependent activation of pGL3ti-(SBE)3 as well 
as TGF--independent activation. This result was 
confirmed by the DNAP assay, in which TCF7L2 was 
able to bind to the SBE upon the activation of ALK5 
(see below). On the other hand, pGL3ti-(SBE)3(TTE)3, 
which includes 3 copies of the TTE in addition to 3 
copies of the SBE, was highly potent in inducing 
TGF- responsiveness. Besides, TCF7L2 further 
potentiated the TGF--induced reporter activity of 
pGL3ti-(SBE)3(TTE)3 although TCF7L2 alone could 
marginally activate this promoter as much as 
pGL3ti-(TTE)3 (Fig. 4C). 
Next, we were prompted to find which SBEs 
could act in concert with TTE upon TGF- stimulation. 
Because there are 5 SBEs in the C region, we tried to 
introduce a mutant to each SBE in the pGL3ti-C 
reporter (Fig. 5A). Of the 5 mutants, the activities of 
pGL3ti-1m, pGL3ti-2m, and pGL3ti-3m upon TGF- 
stimulation were drastically decreased. Furthermore, 
TCF7L2 could not enhance the TGF--induced activity 
of these 3 mutants as much as pGL3ti-C could (Fig. 
5B). When pGL3ti-123m, in which 3 SBEs are 
simultaneously mutated, was transfected into HepG2 
cells, its inducibility by TGF- was lost, although the 
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TCF7L2-mediated activity of pGL3ti-123m could 
remain much weaker than that of pGL3ti-C (Fig. 5C). 
These evidences encouraged us to confirm that an 
artificial luciferase reporter consisting of 3 copies of 
the SBE and 1 copy of TTE (pGL3ti-(SBE)3(TTE)) 
could mimic pGL3ti-C when the cells were stimulated 
with TGF- and/or transfected with TCF7L2. As 
expected, pGL3ti-(SBE)3(TTE) showed a similar 
response to that of pGL3ti-C, whereas 
pGL3ti-(mSBE)3(TTE) did not provide any reporter 
activities upon any combination examined (Fig. 5D). 
These evidences clearly suggested that TTE can 
cooperate with SBEs for enhancement of 
TGF--induced transcription by TCF7L2. 
Binding of TCF7L2 to TTE in the TMEPAI 
gene TCF7L2 or its related molecule, LEF1, is 
known to interact with Smad proteins (17,27). We also 
confirmed that Smad3 can interact with TCF7L2 via its 
MH2 domain (Fig. 6A, B). We next investigated 
whether TCF7L2 can bind to TTE when the TGF- 
signaling pathway is activated. For this purpose, we 
performed a DNAP assay using (SBE)3(TTE) as a 
probe because the TGF--induced activity of 
pGL3ti-(SBE)3(TTE) was drastically enhanced by 
TCF7L2 (Fig. 5D). TCF7L2 could weakly bind to this 
probe in the absence of TGF- signaling, whereas the 
activation of TGF- signaling extensively enhanced the 
affinity of TCF7L2 to the probe in the presence of 
Smad3. On the other hand, the addition of Smad4 did 
not affect this interaction (Fig. 6C). When a probe 
including 3 copies of the mutant SBE and 1 TTE (to 
which neither Smad3 nor Smad4 could bind) was used 
for the DNAP assay, no TGF--dependent binding of 
TCF7L2 was observed (Fig. 6C). These results support 
the idea that TCF7L2 is capable of interacting with 
Smad complex binding to SBE in spite that Smad 
complex does not associate with TCF7L2 binding to 
TTE in the absence of SBE. To further confirm that 
TCF7L2 lies on TTE of the TMEPAI gene in the 
chromatin, we employed a ChIP assay using either 
control rabbit IgG or anti-TCF7L2 rabbit monoclonal 
antibody. As shown in Fig. 6D (upper), TCF7L2 was 
capable of binding to the sequence around TTE of the 
TMEPAI gene upon TGF- stimulation when the 
sonicated chromatin-protein complex was 
immunoprecipitated with anti-TCF7L2 rabbit 
monoclonal antibody. On the other hand, no interaction 
was detected when the control IgG antibody was used 
for immunoprecipitation of the sonicated 
chromatin-protein complex (Fig. 6D, upper). To 
examine whether TCF7L2 could bind to the typical 
TCF7L2-binding site in a TGF--dependent fashion, 
we employed the TCF7L2-binding site in the TCF7 
gene, which is one of the well-known 
Wnt/-catenin/TCF7L2 target genes but not a TGF- 
target gene. As anticipated, we could not see any 
TGF--dependency for TCF7L2-DNA binding (Fig. 
6D, lower). To further confirm that TTE in the intron 1 
contributes to TGF--induced transcription of the 
TMEPAI gene, we also carried out a ChIP assay using 
anti-RNA polymerase II antibody (36). The results 
indicated that the region including TTE was covered 
with RNA polymerase II (Fig. 6E). Thus, TTE might 
be necessary for RNA polymerase II to contact the 
promoter region of the TMEPAI gene. Taken together, 
TCF7L2 is implicated in TGF--dependent activation 
of the TMEPAI gene through its binding to TTE and 
the adjacent SBEs together with the Smad complex. 
 
DISCUSSION 
The Wnt pathway plays a key role in cell fate 
determination, self-renewal and cell differentiation 
 - 10 - 
during the process of vertebrate development. Aberrant 
activation of canonical Wnt pathway leads to neoplasia 
such as colon cancer and leukemia (37-41). On the 
other hand, loss of TGF- signaling by the mutation of 
TGF- type II receptor (TRII) or Smad4 genes is also 
known to be associated with tumor progression in 
colon (2,5,42). Thus, it is possible that integration 
between loss of TGF- signaling and constitutively 
active Wnt signaling might coordinately undergo 
malignant transformation. Indeed, when compound 
heterozygotes carrying both mutations of Smad4 and 
Apc genes in mice were generated, intestinal polyps in 
these compound mice developed into more malignant 
tumors than those in mice carrying Apc mutation in 
one allele (43). 
Previous studies have suggested the 
possibility that the transcript of the TMEPAI gene is 
regulated by TGF- and/or Wnt signaling (8,14,44). 
Furthermore, high expression of TMEPAI was 
observed in several tumors (10,12,13). However, it has 
not been elucidated how the activity of TMEPAI 
promoter is regulated by TGF- and/or Wnt signaling. 
In this study, we showed synergy between TGF- and 
Wnt signals in the regulation of the mouse TMEPAI 
promoter. This cooperative regulation can be mediated 
by interaction between TCF7L2 and Smad3 on the 
enhancer within the first intron of the TMEPAI gene. 
We initially speculated that there was a responsive 
element(s) to be needed for integration between Wnt 
and TGF- signalings in the promoter upstream of the 
transcriptional initiation site of the TMEPAI gene 
because of high similarity within the promoter region 
between human and mouse TMEPAI genes. However, 
neither the stimulation of TGF- nor the expression of 
TCF7L2 did potentiate the activity of 
-1972TMEPAI-luc and -607TMEPAI-luc (Fig. 1D and 
data not shown). Whereas we also found other 
homologous regions just lying downstream of the first 
exon between human and mouse TMEPAI genes, the 
activity of the luciferase reporter including this region 
(pGL3ti-850) was obviously potent upon TGF- and 
Wnt signalings. It is known that nuclear -catenin 
interacts with N-terminal region of TCF7L2 to 
cooperate the transcriptional regulation of Wnt target 
genes (34). TCF7L2(1-30) lacking the -catenin 
binding region could perturb TGF--responsiveness of 
pGL3ti-850. Therefore, the full activation of the 
TMEPAI gene by TGF- might require 
-catenin/TCF7L2 complex. However, the family 
protein of TCF7L2, LEF1 could only marginally 
activate the promoter of the TMEPAI gene (Fig. 2C). 
Our data indicate that TCF7L2 might play a more 
dominant role than LEF1, whereas we are unable to 
exclude the possibility that the high expression of 
LEF1 in cells compared to TCF7L2 expression might 
compensate for its weak transcriptional activity in the 
TMEPAI promoter. Since the TCF/LEF family consists 
of 4 members (TCF7, TCF7L1, TCF7L2, and LEF1), 
and each member has a number of isoforms, it would 
be very interesting to investigate in detail which 
TCF/LEF family member cooperatively functions to 
activate the TMEPAI promoter together with TGF- in 
context-dependent manner. 
Smad2 lacks the ability to bind to DNA 
directly because of the presence of extra amino acid 
sequences proximal to the DNA binding region, 
whereas Smad2exon3 lacking the extra amino acid 
sequences can act like Smad3 (23). Thus, it was 
wondered if Smad2 requires the ability of DNA 
binding for synergistical activation of the TMEPAI 
promoter together with TCF7L2. Indeed, Smad2 
required its DNA binding ability for its cooperative 
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activation of the TMEPAI promoter together with 
TCF7L2. When we further narrowed the TGF-- or 
TCF7L2-responsive element(s) down within the 
sequences from +447 to +1294, the C region possessed 
the highest responsiveness to both TGF- and Wnt 
signalings among three regions. It has been reported 
that the promoters which are regulated by both TGF- 
and Wnt signalings include Smad and TCF/LEF 
binding elements very close each other (17-20,45). As 
anticipated, there are five SBEs and four possible TBEs 
in the C region. Surprisingly, the disruption of one 
possible TBE, termed TTE, drastically reduced the 
promoter activity of the TMEPAI gene 
(pGL3ti-mTBE1) upon stimulation of TGF-, TCF7L2 
expression or the combination. Consequently, TTE was 
the critical cis-element for TGF--mediated activation 
of the TMEPAI promoter. Like the TMEPAI promoter, 
the introduction of a mutation into the TCF/LEF 
binding sites of the Msx2 and gastrin promoters 
revealed abrogation of BMP-dependent and 
TGF--dependent activation, respectively (19,45). 
Obviously, the nucleotide sequence of TTE present in 
the TMEPAI gene (5’-AGTCAAAGT-3’) is somehow 
similar to those of the TCF/LEF binding sites in the 
Msx (5’-ACAAAGG-3’) and gastrin genes 
(5’-AGAGAAATG-3’) (19,45). Thus, we speculated 
that synergistic activation of the TMEPAI gene is 
mediated by a physical association between Smads and 
TCF7L2. Our current evidence and the reports from 
other groups seem that TCF/LEF family surveilles a 
number of TGF--regulated genes by its association 
with Smad proteins. Besides, our artificial 
pGL3ti-(SBE)3-luc, which possesses only SBE 
sequences, could be activated by TCF7L2 without 
TGF- stimulation (Fig. 4C). This result indicates that 
TCF7L2 might indirectly be able to bind to SBE via 
Smad proteins like a co-activator to regulate a 
TGF--target gene(s), whereas Smad complex did not 
seem to possess the ability to bind to TTE via TCF7L2 
(Fig. 6C). Taken together, we speculated that 
synergistic activation of the TMEPAI gene is mediated 
by a physical association between Smads and TCF7L2. 
Indeed, we could observe the interaction of Smad3 
with TCF7L2 in the coimmunoprecipitation assays in 
spite of ligand-independent (or ALK5ca-independent) 
association (Fig. 6B and Suppl. Fig. 8), indicating that 
C-terminal phosphorylation of Smad3 is not required 
for their interaction. In contrast to the results of the 
coimmunoprecipitation assay, TCF7L2 as well as 
Smad3 could bind to the DNA containing SBEs and 
TTE ((SBE)3(TTE)) upon ALK5 activation. However, 
no ALK5ca-dependency was observed when 
(mSBE)3(TTE) was mixed with TCF7L2. These 
evidences indicate that the Smad complex might be 
able to recruit TCF7L2 to TTE in the TMEPAI 
promoter upon stimulation of TGF-. Actually, the 
CHIP assay further supported our concept because 
TCF7L2 could bind to the endogenous TTE in the 
TMEPAI gene upon TGF- stimulation. In addition to 
the cooperative activity between Smads and TCF7L2, 
TGF- and Wnt pathways might also independently 
regulate a TMEPAI promoter (Suppl. Fig. 9). Since we 
showed that TCF7L2 lacking the -catenin binding 
domain can perturb the activation of a TMEPAI 
promoter by TGF-, the canonical Wnt pathway 
through stabilization of -catenin seems to be required 
for the full activation of a TMEPAI promoter. 
The transcript of the TMEPAI gene has been 
reported to be induced by testosterone, its derivatives, 
or mutated p53, and to be implicated in tumorigenesis 
(8-11). Thus, it is suspected that the crosstalk among 
androgen, p53, TGF- and Wnt signaling with respect 
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to TMEPAI expression might be involved in malignant 
transformation. In fact, when intestinal polyps from the 
Apc
Min/+
 mouse were stained with anti-phosphorylated 
Smad2 (index for TGF- signaling), anti--catenin 
(index for Wnt signaling)  and anti-TMEPAI 
antibodies, the cells stained with both 
anti-phosphorylated Smad2 and anti--catenin 
antibodies express TMEPAI at the higher extent than 
those stained with anti-phosphorylated Smad2 alone 
(Suppl. Fig. 3). 
In conclusion, the TMEPAI gene has been 
shown to require both a SBE and TTE for synergistic 
activation in cells. Similar to the gastrin and Msx2 
promoters, the introduction of a mutation in TTE 
showed a more inhibitory effect on the TMEPAI 
expression than did disruption of SBEs, supporting the 
notion that TCF7L2 plays a key role in 
TGF--mediated activation of the TMEPAI gene. 
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FIGURE LEGENDS 
Figure 1. Identification of the TGF- responsive region in the TMEPAI gene 
(A, B) Induction of TMEPAI mRNA by TGF- HepG2 (A) and SC3 cells (B) were treated with 5 ng/mL TGF- 
for indicated times and then analyzed by RT-PCR. (C) Schematic presentation of deletion mutants for luciferase 
constructs. The promoter sequences of the mouse TMEPAI gene are shown. The transcriptional initiation site is 
shown as +1. SBE, Smad binding element; Luc, luciferase. (D) HepG2 cells were transfected with pGL3-basic, 
-1972TMEPAI-luc, or -607TMEPAI-luc, and stimulated with TGF- or BMP. (E) Representation of the first 
intron of the TMEPAI gene from +447 to +1294. Ad MLP, adenovirus major late promoter. (F) Schematic 
representation of pGL3ti-850 (upper). HepG2 cells were transfected with pGL3ti or pGL3ti-850, and stimulated 
with TGF- or BMP (lower). (G) The enhancer activity of the region consisted of 850 nucleotides in the first 
intron of the TMEPAI gene. Parts of the first intron in the TMEPAI gene (see Fig. 1E) were inserted below the 
luciferase gene of -607TMEPAI-luc at both orientations (upper). HepG2 cells were transfected with 
-607TMEPAI-luc-850 or -607TMEPAI-luc-850r and stimulated with TGF- (lower). (H, I) Smad-dependent 
transcriptional activation of the TMEPAI gene. Smad3-deficient MEFs (H) and MDA-MB468 cells (I) were 
transfected with Smad3 and Smad4 together with pGL3ti-850 in the absence or presence of TGF-, respectively. 
 
Figure 2. Crosstalk between TGF- and Wnt signalings to activate the TMEPAI gene  
(A) Expression of TMEPAI mRNA in intestinal adenoma of Apc
Min/+
 mice. WT, intestinal mucosa of wild-type 
mice; Apc
Min/+
 , intestinal polyps of Apc
Min/+
 mice. (B) Reduction of TGF--induced TMEPAI mRNA in TCF7L2 
knocked-down MCF10A1 cells. MCF10A1 cells carrying non-targeting shRNA (control shRNA) or a mixture of 
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TCF7L2 shRNAs were stimulated with TGF- for 2 h. Subsequently, the expression of TCF7L2 mRNA was 
checked using RT-PCR. Since TCF7L2 possesses alternative splicing forms, two PCR products could be seen 
using primers used here. (C) Activation of pGL3ti-850 by TCF7L2 or LEF1. HepG2 cells were transfected with a 
different amount of TCF7L2 or LEF1 together with pGL3ti-850 (upper). Simultaneously, the expression of 
TCF7L2 or LEF1 proteins in HepG2 cells was detected by western blot analysis (lower). (D) Synergistic 
activation of pGL3ti-850 by the combination of ALK5ca with lithium chloride. 293T cells transfected with 
pGL3ti-850 together with or without ALK5ca were cultured in the presence or absence of 20 mM lithium chloride. 
(E) Inhibition of TGF--induced pGL3ti-850 activity by TCF7L2(1-30). HepG2 cells transfected with 
TCF7L2(1-30) were stimulated with TGF-. (F) Synergistic activation of pGL-3ti-850. HepG2 cells transfected 
with Smad3, TCF7L2, -catenin, or their combinations were stimulated with TGF-. (G) Requirement of DNA 
binding ability in Smad proteins for synergistic activation of pGL3ti-850. Smad3-deficient MEF cells transfected 
with Smad2, Smad2exon3, Smad3, and/or TCF7L2 were stimulated with TGF-.  
 
Figure 3. The highest enhancer activity by TGF- and Wnt signalings in the C region of the TMEPAI gene 
(A) Schematic presentation of deletion mutants for luciferase reporters using the first intron of the TMEPAI gene. 
(B, C, D) The reporter activity of each deletion mutant upon stimulation of TGF-, expression of TCF7L2, or 
expression of -catenin. HepG2 cells transfected with pGL3ti-A, pGL3ti-B, or pGL3ti-C were stimulated with 
TGF-, cotransfected with TCF7L2(C), or cotransfected with -catenin (D). (E) Synergistic activation of 
pGL3ti-C by the combination of ALK5ca with lithium chloride. 293T cells transfected with pGL3ti-850 together 
with or without ALK5ca were cultured in the presence or absence of 20 mM lithium chloride. 
 
Figure 4. Identification of TTE 
(A) Schematic presentation of the C region. The small letters written in squares indicate mutated nucleotides for 
TBE1 and TBE2. (B) Requirement of TBE1 for synergistic activation. Schematic representation of mutant 
reporters (upper). HepG2 cells transfected with plasmids described were stimulated with TGF- (lower). (C) 
Effect of concatamers for SBE and/or TTE on TGF--mediated responsiveness in the presence of TCF7L2. 
Constructs of artificial reporters (upper). HepG2 cells transfected with plasmids described were stimulated with 
TGF- (lower). 
 
Figure 5. Importance of particular SBEs together with TTE in the C region of the TMEPAI gene 
(A) Schematic presentation of point mutants for luciferase assay using the C region. Each SBE is numbered from 
the 5’ upstream of the C region. (B) Requirement of 3 distal SBEs for full activation of the pGL3ti-C reporter. 
HepG2 cells transfected with each reporter and TCF7L2 were stimulated with TGF-. (C, D) Loss of synergistic 
activation by introduction of mutations in 3 SBEs for pGL3ti-C (C) or pGL3ti-(SBE)3(TTE) (D). HepG2 cells 
transfected with plasmids described were stimulated with TGF-. 
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Figure 6. TGF--dependent interaction of TCF7L2 with TTE 
(A) Depiction of Smad3 mutants. MH, mad-homology region. (B) Interaction of Smad3 with TCF7L2 via its 
MH2 domain. Immnunoprecipitations were carried out using anti-Flag M5 antibody, and coimmunoprecipitated 
TCF7L2 was detected by western blotting using anti-Myc 9E10 antibody (upper panel). The expression of 
Myc-TCF7L2 and Smad3 mutants conjugated with Flag at the N-terminus was evaluated using anti-Myc 9E10 
(middle panel) and anti-Flag M5 antibodies (lower panel), respectively. WT, wild-type. (C) Requirement of 
Smad-SBE complex for enhanced binding of TCF7L2 to TTE. COS7 cell lysates transfected with plasmids 
indicated were mixed with either biotinated (SBE)3(TTE) or biotinated (mSBE)3(TTE). TCF7L2-DNA complex 
and Smads-DNA complex were detected by western blotting using anti-HA3C10 antibody (upper and third 
panels) and anti-Flag M5 antibody (second and fourth panels), respectively. The expressions of HA-TCF7L2, 
Flag-Smads, and ALK5ca/V5 were evaluated using anti-HA3C10 (fifth panel), anti-Flag M5 (sixth panel), and 
anti-V5 antibodies (bottom panel), respectively. (D, E) Recruitment of TCF7L2 to the C region including TTE 
upon TGF- stimulation. Cross-linked chromatin from HepG2 cells were incubated with anti-TCF7L2 (D) and 
anti-RNA polymerase II antibodies (E). The immunoprecipitated DNA was analyzed by PCR with primers which 
amplify the fragment including TTE in the TMEPAI gene. As a positive control, DNA sequences including 
TCF7L2-binding element (TBE) in the TCF7 gene were also amplified (lower panel in D). As a negative control, 
PCR was performed using DNA immunoprecipitated with mouse control IgG. In parallel, the input DNA was 
amplified by PCR as described above. 
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 Supplementary Figure legends 
Suppl. Fig. 1. Comparison of the beginning 850nt in the first intron between 
human and mouse TMEPAI genes. Identical nucleotides between human and mouse 
show (-). 
 
Suppl. Fig. 2. Effect of Smad2-specific siRNA on TGF--induced pGL3ti-850 
activity. (left) HepG2 cells transfected with Smad2-specific siRNA (Nippon EGT) (1) 
together with pGL3ti-850 were stimulated with TGF-. Control siRNA (Nippon EGT) 
means a non-targeting siRNA. Transfection wasa carried out using lipofectamine 2000. 
(right) The expression of endogenous Smad2 was detected with an anti-Smad2 antibody 
(2) by western blot analysis. 
 
Suppl. Fig. 3. Expression of TMEPAI in tumors. Paraffin-embedded sections of 
intestinal adenoma from Apc
Min/+
 mice. The paraffin-embedded mouse tissues were 
sectioned to a 3 m thickness, deparaffinized in xylene, rehydrated in graded ethanol 
solution, and immersed in citrate-NaOH buffer (10 mM sodium citrate, pH 7.2) for 20 
min at 115˚C to restore antigenicity. Then, the rehydrated sections were incubated 
overnight at 4˚C with mouse anti-TMEPAI monoclonal antibody (Abnova, 1:100), 
rabbit anti-phosphorylated Smad2 antibody (3), or mouse anti--catenin antibody (BD 
Transduction laboratories, 1:100). The sections incubated with the first antibodies were 
washed with PBS and subsequently colored using the Dako EnVision+system HRP 
(DAB) (DakoCytomation). Adenoma was stained for (i) -catenin, (ii) TMEPAI and 
(iii) phosphorylated Smad2 antibodies using 3 consecutive sections. All sections were 
counterstained with hematoxylin. Lower panels show enlarged photos of the regions 
surrounded with squares (upper panels). The broken red and blue lines indicate the 
regions expressing -catenin at low and high levels, respectively. 
 
Suppl. Fig. 4. Expression of TMEPAI mRNA in cells transfected with 
Smad4-specific siRNA, TCF7L2-specific siRNA or both combinations. After indicated 
siRNAs were transfected in MCF10A1 cells, cells were stimulated with TGF- for 2 h. 
The expressions of TMEPAI, TCF7L2, Smad4 and -actin were measured by 
semi-quantitative RT-PCR and normalized using the intensity of the band 
corresponding to -actin. The level of induction was calculated relative to the value for 
control-siRNA-transfected cells in the absence of TGF-. A primer set for human 
Smad4 is 5’-CAAGGTGGAGAGAGTGAAAC-3’ and 
5’-GACGGGCATAGATCACATGA-3’. The other primer sets are described in the text. 
 
Suppl. Fig. 5. Induction of TMEPAI mRNA upon Wnt-3a and/or TGF- 
stimulation. MDA-MB231 cells were stimulated with 200 ng/ml Wnt-3a (R&D 
systems) and/or TGF- for 2 h. The expressions of TMEPAI and -actin were measured 
by semi-quantitative RT-PCR and normalized using the intensity of the band 
corresponding to -actin. The level of induction was calculated relative to the value for 
control-siRNA-transfected cells in the absence of TGF-. The primer sets used here are 
described in the text. 
 
Suppl. Fig. 6. Effect of TCF7L2(1-30) on TGF--induced (CAGA)12-luc activity. 
HepG2 cells transfected with TCF7L2(1-30) were stimulated with TGF-. 
 
Suppl. Fig. 7. Effect of TCF7L2 on TGF--mediated pGL3ti-(mTTE)3 activity. 
HepG2 cells transfected with plasmids described were stimulated with TGF-. 
 
Suppl. Fig. 8. Interaction of Smad3 with TCF7L2 in COS7 cells. COS7 cells were 
transfected with indicated plasmids. Forty hours after transfection, cell lysates were 
immunoprecipitated with anti-Flag antibody, followed by immunoblot using anti-HA 
antibody (upper panel). The expressions of Flag-Smad3, HA-TCF7L2 and ALK5ca/V5 
were evaluated using anti-Flag (2nd panel), anti-HA (3
rd
 panel) and anti-V5 antibodies 
(lower panel), respectively. 
 
Suppl. Fig. 9. A model for activation of a TMEPA1 gene by TGF- and Wnt 
pathways. (a) The TMEPAI promoter with SBEs adjacent to TTE can be activated 
upon TGF- stimulation in the absence of Wnt signal, (b) upon Wnt stimulation without 
TGF- signal or (c) cooperatively in the presence of both TGF- and Wnt signals. 
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